Guimaraes P, Carvalho M, Ruiz J
Sci Rep. 2025; 15(1):8117.
PMID: 40057525
PMC: 11890766.
DOI: 10.1038/s41598-025-91781-8.
Wang H, Liu Z, Peng Z, Lv P, Fu P, Jiang X
PLoS One. 2025; 20(2):e0316552.
PMID: 39903772
PMC: 11793784.
DOI: 10.1371/journal.pone.0316552.
Xiao Y, Zhao M, Wang R, Liu L, Xiang C, Li T
Heliyon. 2025; 11(1):e41241.
PMID: 39844970
PMC: 11750464.
DOI: 10.1016/j.heliyon.2024.e41241.
Haydo A, Schmidt J, Crider A, Kogler T, Ertl J, Hehlgans S
Cell Mol Life Sci. 2025; 82(1):52.
PMID: 39833546
PMC: 11747058.
DOI: 10.1007/s00018-024-05553-0.
He J, Guo J, Sun P
Transl Cancer Res. 2025; 13(12):6862-6879.
PMID: 39816535
PMC: 11730202.
DOI: 10.21037/tcr-24-1258.
Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets.
Jeon S, Jeon Y, Lim J, Kim Y, Cha B, Kim W
Signal Transduct Target Ther. 2025; 10(1):4.
PMID: 39757214
PMC: 11701242.
DOI: 10.1038/s41392-024-02070-1.
Migrasome regulator TSPAN4 shapes the suppressive tumor immune microenvironment in pan-cancer.
Wang L, Xu R, Wu Y
Front Immunol. 2024; 15:1419420.
PMID: 39723210
PMC: 11668678.
DOI: 10.3389/fimmu.2024.1419420.
Is a New Biomarker for Glioma Prognosis.
Liu Z, Liu J, Chen Z, Zhu X, Ding R, Huang S
Biomedicines. 2024; 12(11).
PMID: 39595145
PMC: 11591648.
DOI: 10.3390/biomedicines12112579.
From Genomic Exploration to Personalized Treatment: Next-Generation Sequencing in Oncology.
Vashisht V, Vashisht A, Mondal A, Woodall J, Kolhe R
Curr Issues Mol Biol. 2024; 46(11):12527-12549.
PMID: 39590338
PMC: 11592618.
DOI: 10.3390/cimb46110744.
may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.
Jia Y, Liu M, Liu H, Liang W, Zhu Q, Wang C
Cancer Biol Ther. 2024; 25(1):2425134.
PMID: 39555702
PMC: 11581156.
DOI: 10.1080/15384047.2024.2425134.
Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming promoter methylation.
Modestov A, Zolotovskaia M, Suntsova M, Zakharova G, Seryakov A, Jovcevska I
Ther Adv Med Oncol. 2024; 16:17588359241292269.
PMID: 39525666
PMC: 11544758.
DOI: 10.1177/17588359241292269.
Macrophage polarization-related gene signature for risk stratification and prognosis of survival in gliomas.
Zhong W, Xiong K, Li S, Li C
J Cell Mol Med. 2024; 28(20):e70000.
PMID: 39448550
PMC: 11502305.
DOI: 10.1111/jcmm.70000.
Splicing dysregulation in glioblastoma alters the function of cell migration-related genes.
Seong M, Bak-Gordon P, Liu Z, Canoll P, Manley J
Glia. 2024; 73(2):251-270.
PMID: 39448549
PMC: 11663109.
DOI: 10.1002/glia.24630.
Development of a prognostic model related to homologous recombination deficiency in glioma based on multiple machine learning.
Gong Z, Zhou D, Shen H, Ma C, Wu D, Hou L
Front Immunol. 2024; 15:1452097.
PMID: 39434883
PMC: 11491349.
DOI: 10.3389/fimmu.2024.1452097.
The prognostic significance of androgen receptor expression in gliomas.
Zhao N, Khan R, Hung M, Zhang C, Wang S, Wang T
Sci Rep. 2024; 14(1):22122.
PMID: 39333688
PMC: 11437163.
DOI: 10.1038/s41598-024-72284-4.
Single-cell profiling uncovers proliferative cells as key determinants of survival outcomes in lower-grade glioma patients.
Peng J, Zhang Q, Zhu X, Yan Z, Zhu M
Discov Oncol. 2024; 15(1):445.
PMID: 39276278
PMC: 11401832.
DOI: 10.1007/s12672-024-01302-8.
Key Cell-in-Cell Related Genes are Identified by Bioinformatics and Experiments in Glioblastoma.
Zhang F, Ye J, Zhu J, Qian W, Wang H, Luo C
Cancer Manag Res. 2024; 16:1109-1130.
PMID: 39253064
PMC: 11382672.
DOI: 10.2147/CMAR.S475513.
Novel mitochondrial-related gene signature predicts prognosis and immunological status in glioma.
Liu Y, Cai L, Wang H, Yao L, Zhang K, Chen G
Transl Cancer Res. 2024; 13(7):3338-3353.
PMID: 39145059
PMC: 11319993.
DOI: 10.21037/tcr-23-2072.
Association of M2 macrophages with EMT in glioma identified through combination of multi-omics and machine learning.
Feng P, Liu S, Yuan G, Pan Y
Heliyon. 2024; 10(15):e34119.
PMID: 39145022
PMC: 11320150.
DOI: 10.1016/j.heliyon.2024.e34119.
Targeting ARNT attenuates chemoresistance through destabilizing p38α-MAPK signaling in glioblastoma.
Alafate W, Lv G, Zheng J, Cai H, Wu W, Yang Y
Cell Death Dis. 2024; 15(5):366.
PMID: 38806469
PMC: 11133443.
DOI: 10.1038/s41419-024-06735-1.